寻找TRPV4离子通道和血管生成之间的联系:血管重塑的潜在治疗点
Gabriel Malka1, Vanessa Salucci1, Andreas Bergdahl1
1Department of Health, Kinesiology and Applied Physiology, Concordia University, Montreal, QC H3G 1M8, Canada.
Canadian journal of physiology and pharmacology
|October 7, 2025
概括
暂时受体潜在阴离子通道,类子家族成员4 (TRPV4) 影响血管形成. 抑制TRPV4减少了新血管的生长,同时激活它增加了芽的长度,这表明血管疾病的治疗潜力.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 内皮细胞生物学 内皮细胞生物学
背景情况:
- 血管新生对于缺血性心脏病至关重要,也是癌症治疗的目标.
- 离子和TRPV4通道与影响血管生成的细胞过程有关.
- 特别是TRPV4在内皮细胞中表达,这表明TRPV4在血管形成中的作用.
研究的目的:
- 为了研究短暂受体潜在阴离子通道,类子家族成员4 (TRPV4) 在血管生成中的作用.
- 为了确定TRPV4调制如何影响体外新血管形成.
主要方法:
- 利用3天大的C57Bl/6幼的扩充剂进行了大动脉环测定.
- 用TRPV4激动剂 (GSK1016790) 和抗剂 (HC067047) 治疗的大动脉环.
- 测量了最大的长度和新形成的微容器芽的数量.
主要成果:
- TRPV4抗剂显著降低了新的微血管的数量和长度.
- 作为TRPV4激动剂,显著增加了微血管芽的长度.
- 在试验中,TRPV4活性与血管生成的程度直接相关.
结论:
- TRPV4在调节血管生成和血管重塑方面发挥着重要作用.
- 对于涉及异常血管生成或血液流动受损的疾病,TRPV4代表了潜在的治疗标.
- 对TRPV4调节的进一步研究可能会产生对心血管疾病和癌症的治疗方法.
相关概念视频
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Mechanism of Angiogenesis
6.6K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.6K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K


